Affimed Therapeutics AG and The Leukemia & Lymphoma Society (LLS) today announced a partnership to co-fund a phase 2 trial with the Recruit-TandAb AFM13, a novel tetravalent bispecific antibody directed against human CD30 and CD16A in Hodgkin Lymphoma (HL) patients for whom currently available treatments have failed. AFM13 is a first-in-class immunotherapy drug designed to treat HL patients and patients with CD30-positive malignancies. LLS has committed to investing up to $4.4 million over 2 years to support the project.
Dr. Richard Winneker, SVP Research for LLS, stated, "Though the cure rate for Hodgkin Lymphoma is high compared to other types of blood cancers, refractory and relapsed patients have few therapeutic options. More importantly current treatments for HL patients involve cytotoxic drug therapies and radiotherapy, which are likely responsible for secondary tumors and other considerable long term side effects developing later in a patient's life, leaving open a critical need for safer and more durable therapies. LLS is committed to advancing breakthrough therapies, particularly for patients with unmet medical needs, and Affimed's immunotherapy is emerging as a promising therapeutic option for HL patients."